MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202641085368 A) filed by Sri Eshwar College Of Engineering on July 11, 2026, for Ai-Enabled Microfluidic Microcantilever Biosensor For Point-Of-Care Diagnosis And Staging Of Chronic Kidney Disease.
Inventors include Muthu Shyamala. S; L. Priya; T Suruthikrishna; and Karthik Sriram. Sj.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: Chronic kidney disease (CKD) is a progressive disease that causes the kidneys to stop working as well and to waste excess fluid from the blood, although the course of the disease is typically slow and the kidneys do not cease to work altogether. The leading causes of it are diabetes, hypertension, obesity, cardiovascular disease, and other less common conditions, including glomerulonephritis, recurrent kidney infections, long-term use of certain drugs and certain genetic and environmental factors, such as polycystic kidney disease. The current prevalence of CKD has been estimated at 800 to 850 million people in the world, and at approximately 14% age-standardized prevalence among adults and approximately 1.5 million deaths per year, predominantly in low- and middle income countries with low healthcare infrastructure. The treatment is based on current management, which includes blood pressure and blood sugar control, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dietary modification, and, in advanced stages, dialysis or transplantation, supported by centralizing the diagnosis and individual biomarker testing like serum creatinine. The challenges of these diagnostic methods are that most patients who have early-stage CKD are asymptomatic, traditional laboratory tests (such as creatinine) are used as a late-stage marker of kidney disease, and lab tests are slow to return and require a clinic visit to get. With the present invention, the aforementioned limitations are overcome by providing a novel point-of-care biosensor system capable of detecting 5 urinary biomarkers, Kidney Injury Molecule – 1 (KIM-1), (Neutrophil Gelatinase Associated Lipocalcin) NGAL, Cystatin C, albumin and creatinine, simultaneously from one sample. A microfluidic cartridge evenly distributes the sample onto a concentric array of microcantilevers with a central reference cantilever that compensates for ambient changes, while two-stage machine learning interprets the five-biomarker signature to provide a portable reader with a CKD risk level and disease stage within a few minutes
Disclaimer: Curated by HT Syndication.
